ClinicalTrials.gg
Not yet recruitingNCT07373769Updated Jan 28, 2026

Ultrasound Liver Imaging for Classification of Metabolic Dysfunction-associated Steatotic Liver Disease

An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by University of British Columbia · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
145
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Fatty Liver with a site in Canada — 12 open to participants now, 13 under way, 4 of them phase 3. Fatty Liver · Canada.

Planned enrollment
4th of 13
145 · median 90
Started
2026
with 2 others
Observational
13 of 41
2 open now
Primary completion
2031-12
later than 12 of 12 live
Registered
41st of 41
by date

Among the 41 studies in Fatty Liver with a site in Canada, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2026, is one of 13 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 41st registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

12 of the 41 studies in Fatty Liver with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Fatty Liver with a site in Canada, or all of them as a file.
02

Study summary

Tissue elasticity and viscosity correlate with pathology. These tissue properties are typically evaluated subjectively using palpation. The purpose of "elastography" is to provide an objective elasticity image that is equivalent to the remote palpation of tissue. The investigators have developed elastography imaging systems based on ultrasound and magnetic resonance imaging and have applied them previously to prostate imaging, breast imaging in patients and liver imaging in healthy volunteers.

A first objective of this study is to compare the investigators' ultrasound shear wave absolute vibro-elastography (S-WAVE) technology with the existing clinical standard, FibroScan, and magnetic resonance elastography to quantify liver stiffness in healthy volunteers and in patients suspected of fatty liver disease.

A second objective of this study is to compare ultrasound-based liver tissue fat measurement with MRI-based measurements.

A third objective of this study is to determine whether ultrasound can be used to assess liver inflammation.

Read the detailed description
  1. Purpose The main purpose of this study is to develop ultrasound methods that can identify the stages of metabolic dysfunction-associated steatotic liver disease (MASLD) with Magnetic Resonance Elastography (MRE), MRI Proton Density Fat Fraction (PDFF) and biopsy as the ground truth.
  2. Hypothesis Ultrasound can replace MRI in staging steatosis and fibrosis. Ultrasound can improve the staging of inflammation.
  3. Justification A wide range of pathologies can cause changes in the mechanical properties of human tissue. For this reason, finding a way to non-invasively evaluate tissue stiffness is proving clinically useful. Many liver diseases of varying etiologies including hepatitis, fatty liver disease, alcoholism, and others, present with increased liver stiffness from fibrosis. Fibrosis can lead to various cancers of the liver or cirrhosis, sometimes causing death. It has been estimated that the prevalence of cirrhosis is 4.5% to 9.5% of the general population, indicating a much larger group is inflicted with the varying stages of fibrosis. If dramatic increases in liver stiffness from fibrosis can be caught at an early stage, treatment can be tailored for the patient, and results can be monitored to increase the likelihood of reversal and slow damaging effects.

    Biopsy is traditionally the standard method to diagnose and monitor liver conditions, being widely used since 1958. Some advantages of biopsy include the visualization of fat and iron deposits. Unfortunately, biopsies are not able to show heterogeneity of fibrosis as the reading is often taken from the same location, and consists of only 1/50,000th of the liver volume. Studies have shown discordance in biopsy results from the left to the right lobes in 33% of cases, and 30% misclassification of cirrhotic cases. As well, studies have shown significant inter-observer and intra-observer variation. Finally, a drawback of biopsy that has spurred the transition to non-invasive diagnostic measures, such as elastography, is the associated risk of pain, bleeding, and mortality.

    Various elastography methods have been developed and applied to the liver. Transient elastography, FibroScan (EchoSens, Paris) is the most common type of elastography currently applied to the liver for the measurement of stiffness, indicating fibrotic activity. It uses ultrasound technology with a unidimensional probe to measure the velocity of shear waves. It has become the standard of care in some clinics worldwide as an affordable device that is diagnostically reliable. Although it is pain-free, quick, and convenient, it is only able to collect a very small sample from the right lobe of the liver so cannot capture any heterogeneity and may misrepresent the state of the whole organ. As well, to the best of the investigators' knowledge, stiffness values obtained from FibroScan readings have not been correlated with Magnetic Resonance Elastography values in any direct comparison in the literature, and they result in less reliable results for earlier stages of fibrosis.

    Magnetic Resonance Elastography is another type of elastography applied to the liver. It has shown very high diagnostic accuracy in the staging of patients into fibrotic stages, and is used in some private clinics, primarily in the United States. It allows flexibility in its application and in the protocols used to acquire the data. It has shown great repeatability and reproducibility, and is often effective in patients with higher BMIs. The high costs and complexity associated with MRI scans restricts its usefulness in many areas affected by liver disease.

    The investigators' S-WAVE method is an ultrasound method that will produce two and three-dimensional images, allowing for full visualization of the liver. It is an adjustable multi-frequency technique, which can show large areas of the organ as volumetric elasticity maps. It is affordable and feasible in widespread clinical settings due to the simple hardware needs of an ultrasound device.

    The ultrasound data that is used to measure tissue stiffness can also be used to estimate tissue fat content. Indeed, fatty tissue tends to attenuate ultrasound more than normal tissue. Other characteristics of the ultrasound data (the radio frequency or RF data) are also changed when tissue becomes fatty. The first stage of MASLD is steatosis, an increase proportion of fat in liver tissue, followed by inflammation, followed by tissue scarring and fibrosis.

  4. Objectives

    • To compare the stiffness results obtained from MRE, S-WAVE, and FibroScan in healthy volunteers and in patients to demonstrate strong agreement between S-WAVE with MRE in assessing fibrosis.
    • To compare the MRI proton density fat fraction with ultrasound attenuation and other measures, to demonstrate strong agreement between ultrasound and MRI-PDFF in assessing steatosis.
    • To show that ultrasound can assess the entire MASLD spectrum, including steatosis, fibrosis and inflammation, with biopsy as ground truth.
  5. Research Methods 40 subjects with no history of liver disease, mainly to be recruited from a population of graduate students at UBC, and 105 subjects, with various stages of fibrosis, to be recruited at the Gastroenterology Institute of Research Institute (GIRI) in Vancouver, and VGH will undergo a FibroScan, S-WAVE, and MRI scans including PDFF and MRE.

    The FibroScan and theS-WAVE will be performed by a technician and by a sonographer, respectively, at the GIRI or VGH.

    The MR examination will be performed at the UBC MRI research centre.

    Ten Fibroscan readings will be obtained from the right lobe through the patient's intercostal space. FibroScan displays the median stiffness in kPa as well as the interquartile range. A minimum success rate of 80% with an interquartile range of less than 30% stiffness value is required to accept FibroScan readings. Each subject will undergo the process once.

    S-WAVE is an elastography technique developed at UBC that uses the tissue response to multi-frequency vibrations to estimate the tissue's mechanical properties. The vibrations generate steady-state shear waves in tissue. A series of ultrasound images capture the tissue shear wave motion and a tissue model is used to estimate the underlying mechanical properties. It has already been successfully applied to image the prostate, the breast, the placenta and in the liver.

    The excitation device used is a board placed underneath the patient on the examination bed. The frequencies applied will range from 45 Hz to 80 Hz. The amplitude selected will be sufficient to produce adequate waves in the region of interest, and within the patient's comfort level. A 3D ultrasound probe will be used to obtain image volumes, while being held in place by the sonographer. In addition, a 2D ultrasound transducer will be swept to obtain image volumes in approximately the same location.

    Inter-costal and trans-abdominal images will be obtained according to a repeatable protocol.

    All S-WAVE scans will be performed by two trained and very experienced sonographers, Ms. Vickie Lessoway and Ms. Jan Reid.

    Magnetic Resonance Elastography will be performed on the 3T Philips Elition MR scanner located at the UBC MRI research centre. The scan will begin with axial T1 and T2 images, followed by Diffusion Weighted imaging.

    Then MR elastography examination using the eXpresso sequence and concurrent excitation of tissue will be performed next. The eXpresso sequence has been used in phantom, liver, and prostate studies. The excitation system is an electromagnetic actuator that has been built in house and comprises of loops of wire arranged into a coil. Vibrations result when current is passed through the wires in the presence of the magnetic field of the MR scanner. It is synchronized with the MRI imaging sequence. The shaker will be placed over the right rib cage of the subject whilst lying in a supine position. It will be strapped in place with a velcro belt to avoid any movement. The diameter of the shaker plate is 5 to 10 cm wide. The system is very similar to that used in previous studies elsewhere and to image the prostate and the liver.

    The full MR imaging session will last less than 90 minutes.

    Processing of MRE and VE data occurs offline to extract mechanical property and fat content information. These can then be displayed visually and compared. Both involve processing of the raw ultrasound echo data.

  6. Data Processing All S-WAVE data will be processed by software developed in the Robotics and Control Laboratory at UBC. This software is able to estimate a stiffness value at all imaged points based on a tissue model. The output is a volumetric map of tissue stiffness that can be superimposed on the corresponding B-mode image. Regions of Interest will be selected based on homogenous areas with few blood vessels.

The raw MRE images will be processed with an in-house developed software which filters the data and applies models to calculate the dynamic shear modulus (Gd) and viscosity (Gl) for each pixel. These mechanical properties form a new image that are then superimposed on the standard T2-weighted images for easy visualization. Regions of interest with few blood vessels will be chosen. The average and standard deviation of Gd and Gl will be calculated.

Tissue fat content will be determined by standard MRI PDFF sequences. Tissue fat content will be determined from ultrasound based on quantitative analysis of the raw ultrasound RF data.

Ultrasound image processing will be optimized to match the MRI images (MRI as ground truth for fibrosis and steatosis assessment).

Ultrasound image processing will be optimized to predict inflammation, with biopsy results as ground truth.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Keywords

  • steatosis
  • fibrosis
  • Metabolic dysfunction-associated steatotic liver disease
  • inflammation
  • liver
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers from the University of British Columbia and gastroenterology patients with chronic liver disease from the Vancouver General Hospital or from the St. Paul's hospital, both from Vancouver, British Columbia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between the ages of 19 and 75.
  • healthy volunteers and have no known history of liver disease
  • patients with chronic liver disease, with fibrosis stages F0, F1, F2, F3 or F4.

Exclusion criteria

Exclusion Criteria:

Does not speak and/or read English

CANNOT undergo an MRI exam for one of the following reasons:

  • Retained wires from an electronic implant that has been removed (i.e. pacemaker wires not attached to a pacemaker)
  • Cardiac pacemaker or defibrillator
  • Metal in eye or orbit
  • Ferromagnetic aneurysm clip
  • Pregnancy
  • Makeup tattoos that are not designed to fade over time
  • Stainless steel intrauterine device (IUD)

Depending on the individual situation, patients MAY NOT be able to participate the MRI exam if they have/had any of the following:

  • Artificial heart valve
  • Ear or eye implant
  • Brain aneurysm clip
  • Implanted electronic device (i.e. drug infusion pump, electrical stimulator)
  • Coil, catheter, or filter in any blood vessel
  • Orthopedic hardware (artificial joint, plate, screw, rod)
  • Shrapnel, bullets, or other metal fragments
  • Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks
  • Other metallic prostheses
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
145 participants (estimated)
Patient registry
No

Groups and cohorts

  • healthy volunteers

    who have no known history of liver disease

    Device: Ultrasound and magentic resonance imaging

  • patients with chronic liver disease

    with fibrosis stages F0, F1, F2, F3 or F4.

    Device: Ultrasound and magentic resonance imaging

Interventions

  • DeviceUltrasound and magentic resonance imaging

    For each healthy volunteer and patient, there will be two sessions of imaging. Magnetic resonance imaging, including proton density fat fraction (PDFF) and elastography (MRE) will be acquired. Multi-paramteric, volumetric ultrasound will also be acquired, including shear wave absolute elastography and attenuation, as well as raw radio-frequecy (echo) data. Two systems, a Philips Epiq and a Sonic Incytes Velacur will be used to acquire ultrasound images, including elasticity and attenuation. In addition, Fibroscan measurements (Liver Stiffness measurement and Controlled Attenuation Parameter) will be acquired.

06

What researchers measure

Primary outcomes

  1. Comparison of liver elasticity measurement between magnetic resonance imaging and ultrasound.

    Measurements of liver elasticity measurements acquired with magnetic resonance elastography will be compared to those acquired with ultrasound. Measurements of liver fat content with magnetic resonance imaging and ultrasound will be compared. The measurements will be taken within at most two months of each other. There is no outcome related to this imaging study, it is rather a comparison of liver fibrosis and steatosis image-based measurements, with the goal of offering an alternative to quantitative MRI imaging using quantitative ultrasound. Ability of ultrasound to predict biopsy results will be assessed.

    Time frame: Through study completion, an average of 5 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is volumetric imaging data that, even if de-identified, may allow the subjects to be identified.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Dec 2031, 71 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 28, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Jul 1, 2032
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07373769
Collaborators
Philips Health Care, Sonic Incytes
Responsible party
Septimiu E. Salcudean (Professor, University of British Columbia) — Principal investigator
First posted
Jan 28, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Jul 1, 2032 (estimated)
Last update
Jan 28, 2026

Study contacts

Septimiu Salcudean, PhD
Contact
tims@ece.ubc.ca
1(604)822-3243

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion